GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO)

INR 2852.45

(-3.62%)

Revenue Summary of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited's latest annual revenue in 2023 was 34.53 Billion INR , up 6.2% from previous year.
GlaxoSmithKline Pharmaceuticals Limited's latest quarterly revenue in 2024 Q2 was 10.1 Billion INR , up 24.07% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported a annual revenue of 32.51 Billion INR in annual revenue 2022, down -0.8% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported a annual revenue of 32.78 Billion INR in annual revenue 2021, up 12.05% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly revenue of 8.14 Billion INR for 2024 Q1, down -12.38% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly revenue of 9.29 Billion INR for 2023 Q4, up 15.47% from previous quarter.

Annual Revenue Chart of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Historical Annual Revenue of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Year	Revenue	Revenue Growth
2023	34.53 Billion INR	6.2%
2022	32.51 Billion INR	-0.8%
2021	32.78 Billion INR	12.05%
2020	29.25 Billion INR	-9.27%
2019	32.24 Billion INR	3.08%
2018	31.28 Billion INR	8.94%
2017	28.71 Billion INR	-1.27%
2016	29.08 Billion INR	5.91%
2015	27.46 Billion INR	4.08%
2014	26.38 Billion INR	3.27%
2013	25.54 Billion INR	-3.61%
2012	26.5 Billion INR	9.97%
2011	24.1 Billion INR	12.05%
2010	21.51 Billion INR	12.75%
2009	19.07 Billion INR	12.66%
2008	16.93 Billion INR	5.3%
2007	16.08 Billion INR	1.66%
2006	15.81 Billion INR	4.18%
2005	15.18 Billion INR	7.72%
2004	14.09 Billion INR	0.0%

Year	Revenue	Revenue Growth
2024 Q2	10.1 Billion INR	24.07%
2024 Q1	8.14 Billion INR	-12.38%
2023 Q4	9.29 Billion INR	15.47%
2023 Q2	9.56 Billion INR	25.65%
2023 Q3	8.05 Billion INR	-15.85%
2023 FY	34.53 Billion INR	6.2%
2023 Q1	7.61 Billion INR	-3.28%
2022 FY	32.51 Billion INR	-0.8%
2022 Q1	7.45 Billion INR	-7.97%
2022 Q2	9.16 Billion INR	23.05%
2022 Q3	8.02 Billion INR	-12.5%
2022 Q4	7.87 Billion INR	-1.85%
2021 Q3	8.15 Billion INR	-12.65%
2021 Q2	9.34 Billion INR	30.03%
2021 Q4	8.09 Billion INR	-0.77%
2021 FY	32.78 Billion INR	12.05%
2021 Q1	7.18 Billion INR	-11.72%
2020 Q3	7.91 Billion INR	-9.95%
2020 Q2	8.79 Billion INR	35.57%
2020 Q1	6.48 Billion INR	-16.4%
2020 FY	29.25 Billion INR	-9.27%
2020 Q4	8.13 Billion INR	2.76%
2019 Q4	7.75 Billion INR	-0.36%
2019 FY	32.24 Billion INR	3.08%
2019 Q3	7.78 Billion INR	-11.73%
2019 Q2	8.82 Billion INR	11.94%
2019 Q1	7.87 Billion INR	4.95%
2018 Q3	8.25 Billion INR	1.11%
2018 FY	31.28 Billion INR	8.94%
2018 Q4	7.5 Billion INR	-9.03%
2018 Q2	8.16 Billion INR	10.96%
2018 Q1	7.35 Billion INR	0.0%
2017 Q1	5.82 Billion INR	0.0%
2017 FY	28.71 Billion INR	-1.27%
2016 FY	29.08 Billion INR	5.91%
2015 FY	27.46 Billion INR	4.08%
2014 FY	26.38 Billion INR	3.27%
2013 FY	25.54 Billion INR	-3.61%
2012 FY	26.5 Billion INR	9.97%
2011 FY	24.1 Billion INR	12.05%
2010 FY	21.51 Billion INR	12.75%
2009 FY	19.07 Billion INR	12.66%
2008 FY	16.93 Billion INR	5.3%
2007 FY	16.08 Billion INR	1.66%
2006 FY	15.81 Billion INR	4.18%
2005 FY	15.18 Billion INR	7.72%
2004 FY	14.09 Billion INR	0.0%

Peer Revenue Comparison of GlaxoSmithKline Pharmaceuticals Limited

Name	Revenue	Revenue Difference
Abbott India Limited	58.48 Billion INR	40.951%
Cipla Limited	257.74 Billion INR	86.6%
Gland Pharma Limited	56.41 Billion INR	38.783%
Kopran Limited	6.14 Billion INR	-461.951%
Marksans Pharma Limited	21.77 Billion INR	-58.616%
NGL Fine-Chem Limited	3.38 Billion INR	-919.73%
Pfizer Limited	21.93 Billion INR	-57.476%
Sanofi India Limited	28.51 Billion INR	-21.136%
SMS Pharmaceuticals Limited	7.06 Billion INR	-388.877%